Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Keryx (KERX) Reports Wider-Than-Expected Loss in Q1

Keryx Biopharmaceuticals Inc. KERX is a Boston-based biopharmaceutical company working in the field of renal diseases. The company entered this field with the launch of its first product, Auryxia (ferric citrate) in Dec 2014. The product was approved in the U.S. in Sep 2014 for the control of serum phosphorus levels in patients suffering from chronic kidney disease (CKD) and dependent on dialysis. In Sep 2015, Keryx gained EU approval for Fexeric (EU trade name for Auryxia) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in both dialysis and pre-dialysis patients suffering from CKD.

Keryx’s top line comprises license revenue and revenues earned from Auryxia sales. Meanwhile, ferric citrate is being evaluated in a phase III study for the treatment of iron-deficiency anemia in patients suffering from stage III–V non-dialysis dependent chronic kidney disease (NDD CKD).

Keryx’s track record has been disappointing so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 16.50%. Estimates for 2016 have been static in the last thirty days.

Currently, Keryx has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Keryx’s first-quarter 2016 loss was wider-than-expected. The company posted a loss of 39 cents per share, while the Zacks Consensus Estimate was a loss of 22 cents.

Revenue: Revenues, however, came in-line with our estimates. Keryx posted revenues of $6.8 million, in line with the Zacks Consensus Estimate.

Key Stats: While Auryxia continues to drive revenues at Keryx, the company is solely dependent on the drug for growth. The company recently reported positive data from a  phase III study on ferric citrate for the treatment of iron deficiency anemia in patients suffering from stage III-V non-dialysis dependent CKD and plans to submit a regulatory application for approval to the FDA in the third quarter of 2016 for this indication.

Guidance: Keryx reiterated the guidance provided in Feb 2016. The company expects sales from Auryxia in the range of $31 – $34 million in the U.S. in 2016.

Check back later for our full write up on this Keryx earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. http://woas.zacks.com/adv/7stock_report.pdf?ADID=ZACKS_PFP_7... blog">Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
KERYX BIOPHARMA (KERX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.